摘要
目的观察全反式维甲酸(ATRA)联合高三尖杉酯碱(HHT)治疗初发急性早幼粒细胞白血病(APL)的疗效和生存情况。方法 ATRA联合HHT治疗初治APL患者75例,观察患者临床特征、疗效及生存情况。结果 58例患者获得完全缓解(CR),CR率77.3%;17例患者诱导失败,其中16例死于诱导治疗早期。在平均36个月的中位随访时间中,分别有2例和3例患者死于巩固和维持治疗阶段。患者预期3年总生存率为71.5%,3年无事件生存率为61.0%,获得CR患者3年无事件生存率为78.9%。结论 ATRA联合HHT治疗初发APL患者疗效好,长期生存率高,且价格经济,是APL治疗的合理选择之一。
Objective To observe the clinical outcomes of 75 patients newly diagnosed with acute promyelocytic leukemia（APL） who were treated with all transretinoic acid（ATRA） plus homoharringtonine（HHT） modified protocol.Methods We analyzed the clinical features of these patients and studied ATRA and HHT combination treatment in remission induction and postremission therapy.Results 58 patients achieved morphologic complete remission（CR） with CR rate of 77.3%.The remaining 17 patients had induction failure including 16 patients early mortality.During the median follow up of 36 months,consolidation and maintenance mortalities were 2 and 3 patients,respectively.3-year overall survival（OS） and event-free survival（EFS） rates were 71.5% and 61.0% while the 3-year EFS rate of 58 patients in CR was 78.9%.Conclusion The study showed the anti-leukemic efficacy and reasonable price of ATRA in combination with HHT and that it could be used as a reasonable option in APL therapeutic strategies.
出处
《实用临床医药杂志》
CAS
2011年第1期46-49,共4页
Journal of Clinical Medicine in Practice
